CLINICAL TRIALS PROFILE FOR PROBUPHINE

All Clinical Trials for Probuphine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00447564 ↗	Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence	Completed	Titan Pharmaceuticals	Phase 3	2006-10-01	Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence.
NCT00630201 ↗	Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence	Completed	Titan Pharmaceuticals	Phase 3	2007-10-01	Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patient with opioid dependence. Patients who have completed 24 weeks of treatment in the Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients with Opioid Dependence, will be re-treated with Probuphine over an additional 24 weeks.
NCT00768482 ↗	A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence	Terminated	Titan Pharmaceuticals	Phase 3	2008-09-01	This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).
NCT00772785 ↗	Study of Probuphine in Patients With Opioid Dependence	Terminated	Titan Pharmaceuticals	Phase 3	2008-09-01	Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence. Patients who have completed at least 24 weeks of treatment in the Open-Label, Multi-Center Study of Probuphine in Patients with Opioid Dependence (PRO-807 Study), will be re-treated with Probuphine over an additional 24 weeks.

Clinical Trial Conditions for Probuphine

Condition Name

Condition Name for Probuphine
Intervention	Trials
Opioid Dependence	4
Opioid Dependency	3
Head and Neck Squamous Cell Carcinoma	1

Condition MeSH

Condition MeSH for Probuphine
Intervention	Trials
Opioid-Related Disorders	7
Mucositis	1
Head and Neck Neoplasms	1
Behavior, Addictive	1

Clinical Trial Locations for Probuphine

Trials by Country

Trials by Country for Probuphine
Location	Trials
United States	51

Trials by US State

Trials by US State for Probuphine
Location	Trials
Florida	6
Washington	4
Pennsylvania	4
North Carolina	4
New York	4

Clinical Trial Progress for Probuphine

Clinical Trial Phase

Clinical Trial Phase for Probuphine
Clinical Trial Phase	Trials
Phase 3	7
Phase 2	1

Clinical Trial Status

Clinical Trial Status for Probuphine
Clinical Trial Phase	Trials
Completed	5
Terminated	2
Recruiting	1

Clinical Trial Sponsors for Probuphine

Sponsor Name

Sponsor Name for Probuphine
Sponsor	Trials
Titan Pharmaceuticals	7
National Institute on Drug Abuse (NIDA)	1
Braeburn Pharmaceuticals	1

Sponsor Type

Sponsor Type for Probuphine
Sponsor	Trials
Industry	8
Other	1
NIH	1